Sponsor Study ID:
A First in human, Phase 1 Study to Evaluate the Safety of TTX 080, an HLA G Antagonist, in Subjects With Advanced Solid Tumors
Bladder, Breast, Cervix Uteri, Colon, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Other Female Genital, Other Urinary, Ovary
This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G.
This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor activity of TTX-080 as monotherapy in adults with unresectable or metastatic solid tumors known to express HLA-G.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)